Ocular Myasthenia Gravis (OMG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Ocular Myasthenia Gravis (OMG) Market Outlook

Thelansis’s “Ocular Myasthenia Gravis (OMG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ocular myasthenia gravis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Ocular Myasthenia Gravis (OMG) Overview

Ocular myasthenia gravis (OMG) is an autoimmune disorder characterized by weakness of the extraocular eye muscles, levator palpebrae superioris, and orbicularis oculi, resulting in ptosis and diplopia. It primarily affects the ocular muscles without involving other muscle groups. Ocular manifestations are common in myasthenia gravis, occurring in 15-50% of cases, with fluctuating ptosis, diplopia, and orbicular weakness being the most frequent symptoms. OMG primarily presents with ptosis or diplopia due to ophthalmoplegia, with the hallmark features of fatigability and variability. Clinical examination often confirms these characteristics. Ptosis may affect one or both eyelids, and the upper eyelid elevator muscle exhibits fatigability during sustained upgaze. Enhanced ptosis, known as the "curtain effect," occurs when one eyelid is lifted, and the contralateral eyelid develops or worsens existing ptosis. Several tests are employed to diagnose ocular myasthenia gravis, including sleep, ice, antibody, edrophonium, neostigmine, repetitive nerve stimulation, electrical nerve testing, and scanning. OMG can mimic other pupil-sparing ocular motility disorders, such as fourth, sixth, and partial third nerve palsies, central gaze disorders like internuclear ophthalmoplegia, the one-and-a-half syndrome, and chronic progressive external ophthalmoplegia. Treatment for OMG is determined based on the severity of symptoms during presentation. If myasthenia gravis remains confined to ocular symptoms for one year, the likelihood of progression to generalized myasthenia gravis is 16%. However, if the disease remains localized for three years, the possibility of progression decreases to only 6%.

• The estimated annual incidence of OMG in the United States is 1.13 per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: